Markedly Elevated C-Peptide in Recurrent Hypoglycemia: Endogenous Hyperinsulinism
A C-peptide of 19 ng/mL (~6.3 nmol/L) during hypoglycemia definitively indicates endogenous hyperinsulinism and requires immediate evaluation for an insulinoma or other insulin-secreting disorder. 1
Diagnostic Interpretation
Your patient's C-peptide level is dramatically elevated—approximately 30-fold higher than the diagnostic threshold. According to the Endocrine Society guidelines, C-peptide ≥0.6 ng/mL (0.2 nmol/L) during documented hypoglycemia (<55 mg/dL) confirms endogenous hyperinsulinism 1. Recent data suggests even lower cutoffs (≥0.30 nmol/L) provide 96% sensitivity and 100% specificity 2.
What This Rules In:
- Insulinoma (most likely—accounts for majority of cases)
- Nesidioblastosis/diffuse β-cell hyperplasia
- Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS)
- Post-gastric bypass hypoglycemia (if relevant surgical history)
What This Rules Out:
- Exogenous insulin administration (C-peptide would be suppressed)
- Factitious hypoglycemia from injected insulin
- Most non-insulin-mediated causes of hypoglycemia
Critical Next Steps
1. Complete the Biochemical Workup Immediately
During the next hypoglycemic episode (<55 mg/dL), obtain:
- Insulin level (expect ≥3.0 µU/mL or 18 pmol/L) 1
- Proinsulin (expect ≥5.0 pmol/liter) 1
- β-hydroxybutyrate (expect ≤2.7 mmol/L—suppressed by insulin) 1
- Sulfonylurea/meglitinide screen (must be negative) 1
- Insulin antibodies (to exclude autoimmune hypoglycemia) 1
2. Screen for Oral Hypoglycemic Agents
Even with elevated C-peptide, you must exclude surreptitious sulfonylurea use, which stimulates endogenous insulin secretion 1. This is a critical pitfall—factitious use can mimic insulinoma perfectly.
3. Proceed to Tumor Localization
Once endogenous hyperinsulinism is biochemically confirmed with negative drug screen and no insulin antibodies, immediately pursue imaging 1:
First-line imaging:
- CT pancreas protocol (detects 70-80% of insulinomas) 1
- MRI pancreas (detects ~85%) 1
- Endoscopic ultrasound (>90% sensitivity at experienced centers; allows fine-needle aspiration) 1
If imaging is negative or equivocal:
- Selective arterial calcium stimulation with hepatic venous sampling (regionalizes insulinomas with high sensitivity; >2-fold insulin increase confirms localization) 1
4. Consider MEN-1 Syndrome
Given the severity of presentation, screen for multiple endocrine neoplasia type 1, especially if:
- Age <40 years
- Family history of endocrine tumors
- Multiple pancreatic lesions
- Concurrent pituitary or parathyroid disease 3
Clinical Pearls and Pitfalls
Common diagnostic errors to avoid:
- Don't assume drug-induced hypoglycemia without screening—even patients on GLP-1 agonists can have unmasked insulinomas 3
- Don't rely on random glucose alone—insulinomas may have normal glucose between episodes 4
- Don't dismiss normal imaging—10-15% of insulinomas are <1 cm and may be missed initially 1, 4
- Hemolyzed samples underestimate insulin—C-peptide is more reliable in this setting 2
Why C-peptide is so valuable here: Recent evidence shows C-peptide has superior diagnostic performance compared to insulin (100% specificity vs 92% for insulin at optimal cutoffs) 2. Your patient's extraordinarily high level (19 ng/mL) removes any diagnostic ambiguity.
Immediate Management Considerations
While pursuing diagnosis:
- Frequent small meals with complex carbohydrates
- Avoid fasting states
- Consider diazoxide if hypoglycemia is severe/refractory (inhibits insulin secretion)
- Octreotide as alternative if diazoxide fails 5
Definitive treatment is surgical resection once localized—even in metastatic disease, debulking improves hypoglycemia control 5. Cure rates exceed 90% for benign insulinomas 1.
The combination of recurrent hypoglycemia with C-peptide of 19 ng/mL is pathognomonic for endogenous hyperinsulinism until proven otherwise. Complete the biochemical panel, exclude factitious causes, and proceed directly to localization imaging.